Investors

Investor Relations

DISCOVERING AND DEVELOPING NOVEL THERAPIES THAT CAN OVERCOME RESISTANCE IN CANCER

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer.

Press
Releases
April 15, 2024

ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC

April 8, 2024

ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Upcoming
Events
Apr 17, 2024 at 12:30 PM EDT
Stifel 2024 Virtual Targeted Oncology Forum
INVESTOR
CONTACT

ORIC Pharmaceuticals’ investor relations department can be reached via email at investors@oricpharma.com.

Contact